Month: July 2023

EDF announces the final results of its tender offer for outstanding US dollar-denominated hybrid notes EDF announces the final results of its offer launched on 6 June 2023 to purchase for cash any and all (the “Offer”) of its $1,500,000,000 Reset Perpetual Subordinated Notes, which are admitted to trading on the regulated market of the Luxembourg Stock Exchange (the “Notes”). Summary table of the results of the OfferTitle of Notes CUSIP/ISIN No. Amount Tendered on or prior to the Early Participation Date and Accepted for Purchase Amount Tendered after the Early Participation Date and on or prior to the Expiration Date and Accepted for Purchase Purchase Price(1) Principal Amount Outstanding immediately following the settlement date(2)$1,500,000,000 Reset Perpetual Subordinated Notes CUSIP:268317AM6 (Rule 144A)/F2893TAM8 (Reg S)   ISIN:US268317AM62(Rule...

7 July 2023: Hexagon Agility, a business of Hexagon Composites, has received an inaugural order for Mobile Pipeline® TITAN 450 modules from an industry-leading U.S. energy company. The modules will be used to supply clean natural gas to its fleet to reduce carbon emissions and operating cost. The order represents an estimated value of USD 14.3 million (approx. NOK 155 million). Mobile Pipeline is vital to driving energy transformation by providing alternatives to petroleum fuels with the use of clean and renewable natural gas. Natural gas is today’s low carbon, cost effective alternative energy. With more than 1,800 Mobile Pipeline modules deployed around the world, Hexagon Agility continues to set the standard for safety, reliability, and performance. “We remain committed to driving energy transformation,” says Miguel Raimao, VP...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR   MUTTENZ, July 7, 2023 Clariant, a sustainability-focused specialty chemical company, today provided a trading update based on a preliminary assessment of its Q2 2023 results and adjusted its expectations for FY 2023. The ongoing macro-economic challenges, the slow pace of recovery in China, and the prolonged destocking cycle continues to impact demand in key end markets in the Care Chemicals and the Additives businesses. The strength of the Swiss Franc is creating significant translation impacts in Q2 2023 and FY 2023. However, the improvement of the Catalysts business is on track (excluding sunliquid®). The strong order book in Catalysts is being executed and pricing measures are having positive impacts on the top-line and profitability. Q2 2023 preliminary sales at CHF 1 084 million (compared...

Ad hoc announcement pursuant to Art. 53 LR Urs Scheidegger appointed new CFO of Schweiter Technologies Steinhausen, 7 July 2023 – The Board of Directors of Schweiter Technologies AG has appointed Urs Scheidegger as the new CFO of Schweiter Technologies Group and as a member of management. The 54-year-old, a Swiss citizen, is currently Chief Risk Officer at Schindler Holding. On 1 September 2023, he will succeed Martin Klöti, who is set to leave the Group at the end of September 2023, as previously announced. Urs Scheidegger will assume his new post on 1 September 2023 and take over the responsibilities and function of his predecessor following an intensive induction phase. He holds a master’s degree and doctorate in economics awarded by the University of St. Gallen (HSG). He began his career at McKinsey & Company and since 2002...

ROSEMONT, Ill., July 06, 2023 (GLOBE NEWSWIRE) — Wintrust Financial Corporation (“Wintrust”) (Nasdaq: WTFC) today announced it will release second quarter and year-to-date 2023 earnings results after the market closes on Wednesday, July 19, 2023 and host a conference call on Thursday, July 20, 2023 at 9:00 a.m. (CDT). For individuals wanting to listen to a simultaneous audio-only web cast, this may be accessed at Webcast Link. Individuals interested in participating in the call by addressing questions to management should register for the call at Conference Call Link to receive a dial-in number and unique PIN to access the call seamlessly. It is recommended that you join 10 minutes prior to the event start (although you may register and dial in at any time during the call). An accompanying slide presentation will be...

The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease The Centers for Medicare & Medicaid Services (CMS) announced broader Medicare coverage of LEQEMBI TOKYO and CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous use, making LEQEMBI the first and only approved treatment shown to reduce the rate of disease...

NASHVILLE, Tenn., July 06, 2023 (GLOBE NEWSWIRE) — CapStar Financial Holdings, Inc. (“CapStar”) (NASDAQ: CSTR) announced today that it will issue its second quarter 2023 earnings release after the market closes on July 20, 2023. CapStar will also host a conference call and webcast at 10:00 a.m. Central Time on Friday, July 21, 2023, to discuss its financial results. Analysts and investors may participate in the question-and-answer session. Conference Call and Webcast Information: Date: Friday, July 21, 2023Time: 10:00 a.m. Central Time Telephone Access: Register at https://register.vevent.com/register/BIe83fbf401d174802b64f84d174d92139 to access the live call, including for participants who plan to ask a question during the call. Webcast Access: A live webcast will be available at https://edge.media-server.com/mmc/p/g7zvtfzg. An...

VANCOUVER, British Columbia, July 06, 2023 (GLOBE NEWSWIRE) — Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announces today it has increased its debt by $400,000 to support the launch of Zimed® PF. Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, has agreed to provide financing to Aequus by way of an unsecured demand loan of C$400,000 (the “Loan”). The Loan bears interest at an annual rate of two and a half percent (2.5%) to be calculated and repaid monthly and is repayable on demand. “We remain very excited about the commercial prospects for Zimed and these funds will be used to support operations as we work to a successful launch in August,” said Mr. Janzen. On December 20th, 2022, Aequus Pharmaceuticals announced Health Canada’s approval of Zimed® PF (Bimatoprost 0.03%)...